Home > Publications Database > Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlates. > print

001     285346
005     20260306110151.0
024 7 _ |a 10.1016/j.nbd.2026.107301
|2 doi
024 7 _ |a pmid:41654200
|2 pmid
024 7 _ |a 0969-9961
|2 ISSN
024 7 _ |a 1095-953X
|2 ISSN
037 _ _ |a DZNE-2026-00212
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Maas, Roderick P P W M
|b 0
245 _ _ |a Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlates.
260 _ _ |a [Amsterdam]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772705655_14049
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cognitive deficits are common in spinocerebellar ataxia type 3 (SCA3), but their neurobiological correlates remain largely unknown.To investigate cognitive performance in a large international cohort of SCA3 mutation carriers covering the entire disease course and to explore associations with posterior cerebellar volumes, basal ganglia and thalamus volumes, and plasma neurofilament light chain (NfL) concentration.The Montreal Cognitive Assessment (MoCA) was used to evaluate cognitive impairment in this prospective, observational cohort study involving 13 ataxia referral centers. Standardized motor assessments, brain MR imaging, and peripheral blood biosampling were also performed.MoCA data were collected from 61 pre-ataxic SCA3 mutation carriers, 231 ataxic SCA3 patients, and 111 healthy controls. After adjustments for educational level and age, there were significant differences in MoCA total score, as well as visuospatial/executive, attention, language, and abstraction subscores, between healthy controls and ataxic, but not pre-ataxic individuals. MoCA scores declined with ataxia severity, especially in patients with a lower educational level. Patients with a MoCA score < 26 had lower pallidal volumes and higher plasma NfL concentrations than those with a score ≥ 26. However, only the interaction term between ataxia severity and educational level was independently associated with cognitive performance in multivariable regression analyses containing demographic, clinical, volumetric, and biochemical parameters.Cognitive deficits in SCA3 generally appear after clinical ataxia onset and progress in parallel with ataxia severity, especially in patients with a lower cognitive reserve. Other measured biochemical and imaging parameters did not have a significant additional contribution.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebellum
|2 Other
650 _ 7 |a Cognition
|2 Other
650 _ 7 |a Machado-Joseph disease
|2 Other
650 _ 7 |a Spinocerebellar ataxia type 3
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: blood
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: complications
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: psychology
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: genetics
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: blood
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Mental Status and Dementia Tests
|2 MeSH
693 _ _ |0 EXP:(DE-2719)ESMI-20140101
|5 EXP:(DE-2719)ESMI-20140101
|e European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative
|x 0
700 1 _ |a Garcia-Moreno, Hector
|b 1
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 2
|u dzne
700 1 _ |a Gonzalez, Carlos
|b 3
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 4
|u dzne
700 1 _ |a de Vries, Jeroen J
|b 5
700 1 _ |a Bushara, Khalaf
|b 6
700 1 _ |a Reetz, Kathrin
|b 7
700 1 _ |a Onyike, Chiadi U
|b 8
700 1 _ |a Jacobi, Heike
|b 9
700 1 _ |a Erdlenbruch, Friedrich
|b 10
700 1 _ |a Infante, Jon
|b 11
700 1 _ |a Santana, Magda M
|b 12
700 1 _ |a Hübener-Schmid, Jeannette
|b 13
700 1 _ |a de Almeida, Luís Pereira
|b 14
700 1 _ |a Lima, Manuela
|b 15
700 1 _ |a Giunti, Paola
|b 16
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 17
|u dzne
700 1 _ |a group, ESMI study
|b 18
|e Collaboration Author
700 1 _ |a van de Warrenburg, Bart P C
|b 19
773 _ _ |a 10.1016/j.nbd.2026.107301
|g Vol. 220, p. 107301 -
|0 PERI:(DE-600)1471408-5
|p 107301
|t Neurobiology of disease
|v 220
|y 2026
|x 0969-9961
856 4 _ |u https://pub.dzne.de/record/285346/files/DZNE-2026-00212%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/285346/files/DZNE-2026-00212.pdf
856 4 _ |u https://pub.dzne.de/record/285346/files/DZNE-2026-00212.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:pub.dzne.de:285346
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2810314
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROBIOL DIS : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T14:53:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T14:53:16Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROBIOL DIS : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 1
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21